Mayo Clinic Laboratory and Pathology Research Roundup: September 30
The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
Pancreatic ductal adenocarcinoma (PDAC) is a predominantly fatal common malignancy with inadequate treatment options. Glycogen synthase kinase 3β (GSK-3β) is an emerging target in human malignancies including PDAC. Via Clinical Cancer Research.
Published to PubMed This Week
- Biliary Amyloidoma as a Cause for Pancreatitis.
Clinical Gastroenterology Hepatology
- Seasonality of Bartonella henselae IgM and IgG Antibody Positivity Rates.
Journal of Clinical Microbiology
- Survival Impact of Achieving Minimal Residual Negativity by Multi-Parametric Flow Cytometry in AL Amyloidosis.